Marnie Hoolahan, MBA, is a distinguished executive in the biopharmaceutical sector with over 25 years of experience spanning corporate strategy, sales, new product planning, and business development. Since joining The NemetzGroup in 2011, Ms. Hoolahan has specialized in rare disease consultancy, leading multifaceted Corporate, Medical Affairs, and Commercial engagements. Her contributions to the field include co-authoring two industry submissions to the National Organization for Rare Disorders (NORD) and several analytical e-conversations for The NemetzGroup. Ms. Hoolahan's prior roles at Genzyme Corporation, Bristol Myers Squibb, and Geltex have provided her with a comprehensive understanding of the biopharmaceutical value chain. Ms. Hoolahan's academic background, including a Bachelor of Science in Marketing from Boston College and an MBA in Entrepreneurial Business and Finance from Babson College, underpins her analytical approach to industry challenges. Her ongoing engagement with the academic community is evident in her advisory role to The Termeer Foundation and Wyss Institute PhD entrepreneurs, where she provides pragmatic training on investor presentations. Furthermore, her position on the Life Science Cares Board of Advisors demonstrates her commitment to bridging industry expertise with social responsibility in the life sciences sector.